成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  2. Protein Tyrosine Kinase/RTK Apoptosis
  3. FGFR Apoptosis
  4. Formononetin

Formononetin  (Synonyms: 刺芒柄花素; Biochanin B; Flavosil; Formononetol)

目錄號(hào): HY-N0183 純度: 98.99%
COA 產(chǎn)品使用指南

Formononetin 是一種有效的 FGFR2 抑制劑，IC50 為 ~4.31 μM。 Formononetin 有效抑制血管生成和腫瘤生長(zhǎng)。

MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)

Formononetin Chemical Structure

Formononetin Chemical Structure

CAS No. : 485-72-3

1.  客戶無(wú)需承擔(dān)相應(yīng)的運(yùn)輸費(fèi)用。

2.  同一機(jī)構(gòu)（單位）同一產(chǎn)品試用裝僅限申領(lǐng)一次，同一機(jī)構(gòu)（單位）一年內(nèi)

     可免費(fèi)申領(lǐng)三個(gè)不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶。

規(guī)格 價(jià)格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ￥500
In-stock
5 mg ￥299
In-stock
10 mg ￥448
In-stock
50 mg ￥900
In-stock
100 mg ￥1200
In-stock
500 mg ￥2600
In-stock
1 g   詢價(jià)  
5 g   詢價(jià)  

* Please select Quantity before adding items.

Customer Review

Other Forms of Formononetin:

查看 FGFR 亞型特異性產(chǎn)品:

  • 生物活性

  • 純度 & 產(chǎn)品資料

  • 參考文獻(xiàn)

生物活性

Formononetin is a potent FGFR2 inhibitor with an IC50 of ~4.31 μM. Formononetin potently inhibits angiogenesis and tumor growth[1].

IC50 & Target[1]

FGFR2

4.31 μM (IC50)

細(xì)胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 100 μM
Compound: 13
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
[PMID: 18440233]
A549 ED50
2.87 μg/mL
Compound: 11
Cytotoxicity against human A549 cells after 7 days
Cytotoxicity against human A549 cells after 7 days
[PMID: 8201311]
B16-BL6 IC50
> 100 μM
Compound: 13
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
Cytotoxicity against mouse B16-BL6 cells after 72 hrs by MTT assay
[PMID: 18440233]
BV-2 IC50
> 100 μM
Compound: 19
Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Anti-neuroinflammatory activity against mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 25466192]
BV-2 IC50
13.19 μM
Compound: 2
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay
[PMID: 28911817]
DU-145 IC50
> 100 μM
Compound: Formononetin
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
Cytotoxicity against human DU145 cells after 72 hrs by MTT assay
[PMID: 22633834]
ECa-109 cell line IC50
> 100 μM
Compound: 1
Cytotoxicity against human EC109 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human EC109 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
[PMID: 28038329]
HCT-116 IC50
60.97 μM
Compound: Formononetin
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay
[PMID: 22633834]
HeLa IC50
> 100 μM
Compound: 13
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
[PMID: 18440233]
HeLa IC50
8.51 μM
Compound: Formononetin
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
Cytotoxicity against human HeLa cells after 72 hrs by MTT assay
[PMID: 22633834]
HepG2 IC50
60.5 μM
Compound: 15
Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
Anticancer activity against human HepG2 cells assessed as cell viability after 24 hrs by MTT assay
[PMID: 24974349]
HT-1080 IC50
> 100 μM
Compound: 13
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
Cytotoxicity against human HT1080 cells after 72 hrs by MTT assay
[PMID: 18440233]
HT-29 ED50
6.43 μg/mL
Compound: 11
Cytotoxicity against human HT-29 cells after 7 days
Cytotoxicity against human HT-29 cells after 7 days
[PMID: 8201311]
Lewis lung carcinoma cell line IC50
> 100 μM
Compound: 13
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
Cytotoxicity against mouse LLC cells after 72 hrs by MTT assay
[PMID: 18440233]
MCF7 ED50
1.96 μg/mL
Compound: 11
Cytotoxicity against human MCF7 cells after 7 days
Cytotoxicity against human MCF7 cells after 7 days
[PMID: 8201311]
MDCK CC50
123 μM
Compound: 3
Cytotoxicity against MDCK cells after 72 hrs
Cytotoxicity against MDCK cells after 72 hrs
[PMID: 24313801]
MDCK IC50
38.2 μM
Compound: 3
Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against Influenza A virus J/8178/09 infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
[PMID: 24313801]
MDCK IC50
42.6 μM
Compound: 3
Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
Antiviral activity against Influenza A virus (A/Hong Kong/1/1968(H3N2)) infected in MDCK cells assessed as inhibition of virus-induced cytopathic effect after 48 hrs
[PMID: 24313801]
MGC-803 IC50
> 100 μM
Compound: 1
Cytotoxicity against human MGC803 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human MGC803 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
[PMID: 28038329]
N9 IC50
> 100 μM
Compound: 4
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antineuroinflammatory activity in mouse N9 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 28073678]
PC-3 IC50
57.01 μM
Compound: 1
Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
Cytotoxicity against human PC3 cells assessed as inhibition of cell viability after 48 hrs by MTT assay
[PMID: 28038329]
RAW264.7 IC50
56.1 μM
Compound: 6
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay
[PMID: 23743282]
SGC-7901 IC50
2.17 μM
Compound: Formononetin
Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
Cytotoxicity against human SGC7901 cells after 72 hrs by MTT assay
[PMID: 22633834]
SH-SY5Y IC50
> 100 μM
Compound: Formononetin
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
Cytotoxicity against human SH-SY5Y cells after 72 hrs by MTT assay
[PMID: 22633834]
U-937 IC50
44 μM
Compound: 6, formononetin
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 48 hrs by WST-8 assay
[PMID: 17158054]
U-937 IC50
45 μM
Compound: 6, formononetin
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 72 hrs by WST-8 assay
[PMID: 17158054]
U-937 IC50
50 μM
Compound: 6, formononetin
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
Antiproliferative activity against human U937 cells after 24 hrs by WST-8 assay
[PMID: 17158054]
體外研究
(In Vitro)

Formononetin 是從 Astragalus membranaceus 中分離出來(lái)的主要異黃酮成分之一，已被證明具有多種藥理益處。Formononetin 在人結(jié)腸癌細(xì)胞中具有抗血管生成活性。Formononetin 還通過(guò)下調(diào)人前列腺癌細(xì)胞中的 Akt/細(xì)胞周期蛋白 D1/CDK4 促進(jìn)細(xì)胞周期停滯[1]。
Formononetin (25-150 μM) 顯著降低 FGF2 刺激的內(nèi)皮細(xì)胞增殖[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay[1]

Cell Line: HUVECs
Concentration: 0, 10, 25, 50, 75, 100, and 150 μM
Incubation Time:
Result: Significantly decreased the proliferation of HUVECs stimulated by FGF2 in a dose-dependent manner, while had little inhibitory effects on HUVECs that were not stimulated by FGF2.
體內(nèi)研究
(In Vivo)

Formononetin 顯著抑制腫瘤體積，并且與載體組相比，F(xiàn)ormononetin 處理組的腫瘤重量得到顯著抑制。Formononetin 處理耐受性良好，賦形劑組與 Formononetin 處理組體重?zé)o顯著差異[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: BALB/c nude mice bearing MDA-MB-231 xenografts[1]
Dosage: 100 mg/kg
Administration: Treated daily by intragastric administration for 25 days
Result: Inhibited breast cancer growth and angiogenesis in vivo.
分子量

268.26

Formula

C16H12O4
CAS 號(hào)
性狀

固體

顏色

White to off-white

中文名稱

刺芒柄花素；生原禪寧 B；素普拉腦； 芒柄花素
結(jié)構(gòu)分類
初始來(lái)源
運(yùn)輸條件

Room temperature in continental US; may vary elsewhere.
儲(chǔ)存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 1 year
-20°C 6 months
溶解性數(shù)據(jù)
細(xì)胞實(shí)驗(yàn)： 

DMSO 中的溶解度 : ≥ 35 mg/mL (130.47 mM; 吸濕的 DMSO 對(duì)產(chǎn)品的溶解度有顯著影響，請(qǐng)使用新開(kāi)封的 DMSO)

* "≥" means soluble, but saturation unknown.

配制儲(chǔ)備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 3.7277 mL 18.6386 mL 37.2773 mL
5 mM 0.7455 mL 3.7277 mL 7.4555 mL
查看完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

  • 摩爾計(jì)算器

  • 稀釋計(jì)算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動(dòng)物實(shí)驗(yàn)：

請(qǐng)根據(jù)您的 實(shí)驗(yàn)動(dòng)物和給藥方式 選擇適當(dāng)?shù)娜芙夥桨浮?

以下溶解方案都請(qǐng)先按照 In Vitro 方式配制澄清的儲(chǔ)備液，再依次添加助溶劑：
——為保證實(shí)驗(yàn)結(jié)果的可靠性，澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；體內(nèi)實(shí)驗(yàn)的工作液，建議您現(xiàn)用現(xiàn)配，當(dāng)天使用；
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比；如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶

  • 方案 一

    請(qǐng)依序添加每種溶劑： 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: 2.5 mg/mL (9.32 mM); 懸濁液; 超聲助溶

    此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 400 μL PEG300 中，混合均勻；再向上述體系中加入 50 μL Tween-80，混合均勻；然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL。

    生理鹽水的配制：將 0.9 g 氯化鈉，溶解于 ddH?O 并定容至 100 mL，可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請(qǐng)依序添加每種溶劑： 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: 2.5 mg/mL (9.32 mM); 懸濁液; 超聲助溶

    此方案可獲得 2.5 mg/mL的均勻懸濁液，懸濁液可用于口服和腹腔注射。

    以 1 mL 工作液為例，取 100 μL 25.0 mg/mL 的澄清 DMSO 儲(chǔ)備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中，混合均勻。

    2 g SBE-β-CD（磺丁基醚 β-環(huán)糊精）粉末定容于 10 mL 的生理鹽水中，完全溶解至澄清透明。

以下溶解方案，請(qǐng)直接配制工作液。建議現(xiàn)用現(xiàn)配，在短期內(nèi)盡快用完。 以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比； 如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象，可以通過(guò)加熱和/或超聲的方式助溶。

  • 方案 一

    請(qǐng)依序添加每種溶劑： 50% PEG300    50% Saline

    Solubility: 5 mg/mL (18.64 mM); 懸濁液; 超聲助溶

  • 方案 二

    請(qǐng)依序添加每種溶劑： 0.5% CMC-Na/saline water

    Solubility: 25 mg/mL (93.19 mM); 懸濁液; 超聲助溶

動(dòng)物溶解方案計(jì)算器
請(qǐng)輸入動(dòng)物實(shí)驗(yàn)的基本信息：

給藥劑量

mg/kg

動(dòng)物的平均體重

g

每只動(dòng)物的給藥體積

μL

動(dòng)物數(shù)量

只
由于實(shí)驗(yàn)過(guò)程有損耗，建議您多配一只動(dòng)物的量
請(qǐng)輸入您的動(dòng)物體內(nèi)配方組成：
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
如果您的動(dòng)物是免疫缺陷鼠或者體弱鼠，建議 DMSO 中的在最后工作液體系中的占比盡量不超過(guò) 2%。
方案所需 助溶劑 包括：DMSO， ，均可在 MCE 網(wǎng)站選購(gòu)。 ，Tween 80，均可在 MCE 網(wǎng)站選購(gòu)。
計(jì)算結(jié)果
工作液所需濃度 : mg/mL
儲(chǔ)備液配制方法 : mg 藥物溶于 μL  DMSO（母液濃度為 mg/mL）。
您所需的儲(chǔ)備液濃度超過(guò)該產(chǎn)品的實(shí)測(cè)溶解度，以下方案僅供參考，如有需要，請(qǐng)與 MCE 中國(guó)技術(shù)支持聯(lián)系。
動(dòng)物實(shí)驗(yàn)體內(nèi)工作液的配制方法 : 取 μL DMSO 儲(chǔ)備液，加入 μL 。 μL ，混合均勻至澄清，再加 μL Tween 80，混合均勻至澄清，再加 μL 生理鹽水。
連續(xù)給藥周期超過(guò)半月以上，請(qǐng)謹(jǐn)慎選擇該方案。
請(qǐng)確保第一步儲(chǔ)備液溶解至澄清狀態(tài)，從左到右依次添加助溶劑。您可采用超聲加熱 （超聲清洗儀，建議頻次 20-40 kHz），渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 98.99%

參考文獻(xiàn)

完整儲(chǔ)備液配制表

* 請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲(chǔ)備液；一旦配成溶液，請(qǐng)分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。
儲(chǔ)備液的保存方式和期限：-80°C, 1 year; -20°C, 6 months。-80°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?年內(nèi)使用， -20°C儲(chǔ)存時(shí)，請(qǐng)?jiān)?個(gè)月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.7277 mL 18.6386 mL 37.2773 mL 93.1932 mL
5 mM 0.7455 mL 3.7277 mL 7.4555 mL 18.6386 mL
10 mM 0.3728 mL 1.8639 mL 3.7277 mL 9.3193 mL
15 mM 0.2485 mL 1.2426 mL 2.4852 mL 6.2129 mL
20 mM 0.1864 mL 0.9319 mL 1.8639 mL 4.6597 mL
25 mM 0.1491 mL 0.7455 mL 1.4911 mL 3.7277 mL
30 mM 0.1243 mL 0.6213 mL 1.2426 mL 3.1064 mL
40 mM 0.0932 mL 0.4660 mL 0.9319 mL 2.3298 mL
50 mM 0.0746 mL 0.3728 mL 0.7455 mL 1.8639 mL
60 mM 0.0621 mL 0.3106 mL 0.6213 mL 1.5532 mL
80 mM 0.0466 mL 0.2330 mL 0.4660 mL 1.1649 mL
100 mM 0.0373 mL 0.1864 mL 0.3728 mL 0.9319 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱：

  

* 需求量：

* 客戶姓名：

 

* Email：

* 電話：

 

* 公司或機(jī)構(gòu)名稱：

   留言給我們：

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱：
Formononetin
目錄號(hào)：
HY-N0183
需求量：